Supplementary Material

Saxagliptin cardiotoxicity in chronic heart failure: the role of DPP4 in the regulation of neuropeptide tone

Imre Vörös[1,2,3], Zsófia Onódi[1,2,3], Viktória Éva Tóth[1,2,3], Tamás G. Gergely[1,2,3], Éva Sághy[1], Anikó Görbe[1,4], Ágnes Kemény[5,6,7], Przemyslaw Leszek[8], Zsuzsanna Helyes[5,6,9], Péter Ferdinandy[1,4], Zoltán V. Varga[1,2,3*]

[1]Cardiometabolic Research Group and MTA-SE System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, 1085 Budapest, Hungary; voros.imre@med.semmelweis-univ.hu (I.V.); onodi.zsofia@med.semmelweis-univ.hu (Z.O.); toth.viktoria@med.semmelweis-univ.hu (V.É.T.); gergely.tamas@med.semmelweis-univ.hu (T.G.G.); saghy.eva@med.semmelweis-univ.hu (É.S.); gorbe.aniko@med.semmelweis-univ.hu (A.G.); peter.ferdinandy@pharmahungary.com (P.F.); varga.zoltan@med.semmelweis-univ.hu (Z.V.V.);

[2]HCEMM-SU Cardiometabolic Immunology Research Group, Semmelweis University, 1085 Budapest, Hungary;

[3]MTA-SE Momentum Cardio-Oncology and Cardioimmunology Research Group, Semmelweis University, 1085 Budapest, Hungary;

[4]Pharmahungary Group, 6722 Szeged, Hungary;

[5]Szentágothai János Research Centre, University of Pécs, 7624 Pécs, Hungary; kemeny.agnes@pte.hu (Á.K.); zsuzsanna.helyes@aok.pte.hu (Z.H.);

[6]Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, 7624 Pécs, Hungary;

[7]Department of Medical Biology, University of Pécs, 7624 Pécs, Hungary;

[8]Department of Heart Failure and Transplantology, Cardinal Stefan Wyszyński National Institute of Cardiology, 04-628 Warszawa, Poland; przemyslaw.leszek@ikard.pl (P.L.);

[9]PharmInVivo Ltd. 7629 Pécs, Hungary

* Correspondence: varga.zoltan@med.semmelweis-univ.hu; Tel.: +36-1-2104416

SUPPLEMENTARY TABLES

Supplementary Table S1 – Patient characteristics in Western blot experiments

Parameter	CON	ICM	DCM
Gender (male/female)	6/2	8/1	8/0
Age (year)	33 (23-52)	58 (39-66)	48 (27-58)
BMI (kg/m^2)	25 (20-32)	27 (20-33)	29 (21-40)
Ejection fraction (%)	-	21 (13-33)	19 (5-33)
N-terminal pro-BNP (pg/ml)	-	3328 (338-8024)	5308 (1001-14750)
Medications			
Norepinephrine	7	0	1
ACE inhibitors	0	7	6
Beta receptor blockers	1	9	8
Mineralocorticoid receptor inhibitors	0	9	2
Furosemide	1	0	0
Mannitol	1	0	0
Digoxin	0	1	1
Mexiletine	0	1	1
Amiodarone	0	3	5
Anticoagulants	1	5	4
Antiplatelets	0	7	0
Dopamine	0	3	3
Dobutamine	0	3	4
Sildenafil	0	3	2
Statins	0	9	2
Allopurinol	0	1	3

Clinical parameters of the human interventricular tissue samples used in Western blot experiments. Data are expressed as mean and range. Abbreviations: CON: control; ICM: ischemic cardiomyopathy; DCM: dilated cardiomyopathy

Supplementary Table S2 – Patient characteristics in radioimmunoassay and ELISA experiments

Parameter	CON	ICM	DCM
Gender (male/female)	4/6	9/1	10/0
Age (year)	38 (17-52)	62 (45-74)	48 (27-60)
BMI (kg/m^2)	26 (20-34)	26 (20-33)	27 (20-39)
Ejection fraction (%)	-	21 (10-33)	17 (5-25)
N-terminal pro-BNP (pg/ml)	-	3071 (338-7699)	8632 (1001 - 35000)
Medications:			
Norepinephrine	10	0	1
ACE inhibitors	0	8	8
Beta receptor blockers	1	10	10
Mineralocorticoid receptor inhibitors	0	10	9
Furosemide	2	0	0
Mannitol	2	0	0
Digoxin	0	2	2
Mexiletine	0	1	1
Amiodarone	0	2	6
Anticoagulants	1	6	6
Antiplatelets	0	7	0
Dopamine	4	2	3
Dobutamine	0	2	4
Sildenafil	0	3	2
Statins	0	10	1
Allopurinol	0	4	3

Clinical parameters of the human interventricular tissue samples used in radioimmunoassay and ELISA experiments. Data are expressed as mean and range. Abbreviations: CON: control; ICM: ischemic cardiomyopathy; DCM: dilated cardiomyopathy

SUPPLEMENTARY FIGURES



Supplementary Figure S1 - Representative confocal microscopy images of RNA Scope® negative control (green, red) in histological samples of human control left ventricle. Cells were counterstained with DAPI (blue). Scale bar: 25 µm.